Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SI | P14410 | 2/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22798929 | 0.85 | PPARA (0.44) | RXRAPPARAPPARG | |
| SCHEMBL19469539 | 0.84 | GAA (0.39) | MGAMGAASIMGAM2RXRA | |
| SCHEMBL13903650 | 0.78 | HIF1A (0.39) | GAANPSR1KDM4EMAPTPOLB | |
| SCHEMBL20819443 | 0.77 | PPARA (0.37) | SMN1; SMN2PPARAPPARGMEN1ALDH1A1 | |
| SCHEMBL6798457 | 0.77 | SOD1 (0.44) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL6798455 | 0.77 | SOD1 (0.44) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL6799093 | 0.77 | SOD1 (0.44) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL13913065 | 0.76 | PPARA (0.43) | RXRAPPARAPPARGKDM4EFAAH | |
| SCHEMBL23618135 | 0.75 | BCHE (0.43) | MGAMGAASIMGAM2RXRA | |
| SCHEMBL4769228 | 0.75 | ALDH1A1 (0.39) | GAANPSR1PPARAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-04-02 | — | — | US | disclosed |
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-10 | — | — | US | disclosed |
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246454-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | MGAM 4109/4885GAA 243/4885SI 1961/4885 |
| US-20150353544-A1 | NOVEL SUBSTITUTED PYRIDO-PIPERAZINONE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MGAM 4251/4885GAA 181/4885SI 2138/4885 |
| US-10562897-B2 | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators | BACE1, BACE2, PSEN1 | MGAM 4109/4885GAA 243/4885SI 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.